natgillin/translations-raw huggingface dataset:
For additional information contact your healthcare professional.
Za dodatne informacije se obrnite na vašega zdravstvenega delavca.
For additional information on deaths in the C209 trial, see section 4.8.
Za dodatne informacije o smrtnih primerih v študiji C209 glejte poglavje 4.8.
For additional information on the co-administration with corticosteroids, see section 4.5. Please refer to the SmPC of co-administered 5-HT3 antagonist medicinal products.
Za dodatne informacije o sočasni uporabi s kortikosteroidi glejte poglavje 4.5. Glejte tudi SmPC za sočasno uporabljeni antagonist 5-HT3.
For additional information on the co-administration with corticosteroids, see section 4.5. Please refer to the Summary of Product Characteristics of co-administered 5-HT3 antagonist medicinal products.
Za dodatne informacije o sočasni uporabi s kortikosteroidi glejte poglavje 4.5. Glejte tudi SmPC za sočasno uporabljeni antagonist 5-HT3.
For additional information on the effect of ritonavir on co-administered protease inhibitor metabolism, see Section 4.5 and refer to the Summary of Product Characteristics of the particular co-administered PIs.
Za dodatne informacije o učinku ritonavirja na presnovo sočasno uporabljenega zaviralca proteaz glejte poglavje 4.5 in povzetek glavnih značilnosti za posamezni sočasno uporabljeni zaviralec proteaz.
For additional information regarding sodium content of Macugen, see section 2.
Za dodatne informacije o vsebnosti natrija v zdravilu Macugen glejte poglavje 2.
For additional information, contact your healthcare professional.
Za dodatne informacije, se obrnite na vašega zdravstvenega delavca.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis- metritisagalactia syndrome) with appropriate antibiotic therapy.
Za pomožno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalakcije) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (Mastitis-Metritis- Agalactia syndrome MMA) with appropriate antibiotic therapy.
Za podporo zdravljenju septikemije in toksemije ob oprasitvi (sindrom mastitis-metritis-agalakcija - MMA) skupaj z ustreznim antibiotičnim zdravljenjem.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (Mastitis-Metritis- Agalactia syndrome MMA) with appropriate antibiotic therapy.
Za podporo zdravljenju septikemije in toksemije ob oprasitvi (sindrom mastitis-metritis-agalakcija MMA) skupaj z ustreznim antibiotičnim zdravljenjem.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
Za pomožno terapijo pri zdravljenju puerperalnih septikemij in zastrupitvah krvi ( MMA sindrom) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
Za pomožno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalakcije) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
Za pomožno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalaktije) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
Za pomožžno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalakcije) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Kot dodatna terapija pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitis-metritis-agalactia) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Kot dodatna terapija pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitis-metritis-agalactia, MMA) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
Za pomožno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalakcije) ob ustreznem antibiotičnem zdravljenju.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis–metritis–agalactia syndrome) with appropriate antibiotic therapy.
Za pomožno terapijo pri zdravljenju poporodnih septikemij in zastrupitvah krvi ( MMA sindrom) ob ustreznem antibiotičnem zdravljenju.
For administration by ILP Intraarterial use
Za uporabo v postopku izolirane perfuzije okončin Intraarterijska uporaba
For administration in the other nostril, pinch and remove the dose-divider clip from plunger.
Za vnos v drugo nosnico odščipnite in odstranite sponko za razdelitev odmerka z bata.
For administration instructions, see section 6.6.
Za navodilo za injiciranje glejte poglavje 6.6.
For administration of a 0.25 ml dose in children aged 2 months to < 3 years, follow the steps below:
Pri dajanju 0,25 ml odmerka otrokom, starim 2 meseca do < 3 leta, upoštevajte spodnje korake:
For administration of Rebif, please read the following instructions carefully:
Za uporabo zdravila Rebif pozorno preberite naslednja navodila:
For administration of the full 0.5 ml dose follow the steps below:
Pri dajanju celega 0,5 ml odmerka upoštevajte spodnje korake:
For administration submucosally to the inside of the upper lip.
Za dajanje submukozno na notranjo stran zgornje ustnice
For administration the use of a luer-lock syringe is required.
Pri dajanju je treba uporabiti brizgo s sistemom luer-lock.
For administration the use of a luer-lock syringe is required.
Pri dajanju uporabljamo brizgo s sistemom luer-lock.
For administration the use of a luer-lock syringe is required.
Za uporabo potrebujete brizgo z luer lock nastavkom.
For administration through water lines using a dosing pump (proportioner), dilute the reconstituted vaccine in the needed volume of the dosing pump stock solution.
Če uporabljate vodne cevi in črpalko za odmerjanje (dozirnik), rekonstituirano cepivo razredčite v potrebni količini osnovne raztopine v črpalki za odmerjanje.
For administration using bowls or tanks, dilute the reconstituted vaccine in the volume of water that the pigs will drink during a 4-hour time period.
Če uporabljate sklede ali cisterne, rekonstituirano cepivo razredčite v količini vode, ki jo bodo prašiči popili v 4-urnem obdobju.
For administration with a syringe pump: Calculate the required volume of Erbitux.
Za uporabo s črpalko za brizgo: Izračunajte potreben volumen zdravila Erbitux.
For administration with infusion pump or gravity drip (diluted with sterile sodium chloride 9 mg/mL (0.9%) solution): Take an infusion bag of adequate size of sterile sodium chloride 9 mg/mL (0.9%) solution.
Za uporabo z infuzijsko črpalko ali s težnostno kapalno infuzijo (razredčeno s sterilno raztopino natrijevega klorida 9 mg/ml (0,9%)): Vzemite vrečko za infundiranje primerne velikosti s sterilno raztopino natrijevega klorida 9 mg/ml (0,9%).
For administration with infusion pump or gravity drip (diluted with sterile sodium chloride 9 mg/mL (0.9%) solution): Take an infusion bag of adequate size of sterile sodium chloride 9 mg/mL (0.9%) solution.
Za uporabo z infuzijsko črpalko ali s težnostno kapalno infuzijo (razredčeno s sterilno raztopino natrijevega klorida 9 mg/ml, (0,9%)): Vzemite vrečko za infundiranje primerne velikosti s sterilno raztopino natrijevega klorida 9 mg/ml (0,9%).
For administration with infusion pump or gravity drip (undiluted): Calculate the required volume of Erbitux.
Za uporabo z infuzijsko črpalko ali težnostno kapalno infuzijo (nerazredčeno): Izračunajte potrebni volumen zdravila Erbitux.
For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed below) to obtain a final voriconazole solution containing 0.5-5 mg/ml.
Potrebni volumen pripravljenega koncentrata se nato doda eni od priporočenih združljivih infuzijskih raztopin, naštetih spodaj, da nastane končna raztopina zdravila Vorikonazol Hospira , ki vsebuje od 0,5 do 5 mg/ml vorikonazola.
For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed in the table below) to obtain a final voriconazole solution containing 0.5-5 mg/ml.
Za aplikacijo se potrebni volumen rekonstituiranega koncentrata doda priporočeni združljivi raztopini za infundiranje (navedene so v preglednici spodaj), da nastane končna raztopina zdravila VFEND, ki vsebuje 0,5–5 mg/ml.
For administration, vaccine devices should be used in accordance with the device instructions provided by the manufacturer.
Opremo za cepljenje uporabljajte v skladu z izdelovalčevimi navodili za uporabo opreme.
For adsorbent, see section 2.
Za adsorbense glejte poglavje 2.
For adult patients who use 0.5 µg/kg PegIntron monotherapy, dose reduction may be accomplished by reducing the prescribed volume by one-half as shown in Table 3b.
Za odrasle bolnike, ki uporabljajo 0,5 µg/kg zdravila PegIntron v monoterapiji, zmanjšanje odmerka lahko dosežemo z zmanjšanjem predpisanega volumna za polovico, kot je prikazano v preglednici 3b.
For adults
pri odraslih
For adults
za odrasle
For adults and adolescents aged 16 years of age and older, 1 ml of the lower strength is given at each injection.
Pri odraslih in mladostnikih, ki so stari 16 let in več, se z vsako injekcijo vbrizga 1 ml zdravila nižje jakosti.
For adults and children Abseamed is given as an injection either into a vein (intravenously) or a tube that goes into a vein.
Odraslim in otrokom se daje zdravilo Abseamed v obliki injekcije bodisi v veno (intravensko) ali s cevko, ki gre v veno.
For adults and children Binocrit is given as an injection either into a vein (intravenously) or a tube that goes into a vein.
Odraslim in otrokom se daje zdravilo Binocrit v obliki injekcije bodisi v veno (intravensko) ali s cevko, ki gre v veno.
For adults and children Epoetin alfa HEXAL is given as an injection either into a vein (intravenously) or a tube that goes into a vein.
Odraslim in otrokom se daje zdravilo Epoetin alfa HEXAL v obliki injekcije bodisi v veno (intravensko) ali s cevko, ki gre v veno.
For adults and older people:
Za odrasle in starejše:
For adults and paediatric aHUS patients supplemental dosing of Soliris is required in the setting of concomitant PE/PI (plasmapheresis or plasma exchange, or fresh frozen plasma infusion):
Za odrasle in pediatrične bolnike z aHUS je dodatno odmerjanje zdravila Soliris potrebno v primeru sočasne PE/PI (plazmafereza ali izmenjalna transfuzija s plazmo ali infuzija sveže zamrznjene plazme):
For adults with a BMI of 28 or above Weight loss aid
Za odrasle z ITM enakim ali večjim od 28 Zdravilo za zmanjševanje telesne mase
For adults with a BMI of 28 or above Weight loss aid.
Za odrasle z ITM enakim ali večjim od 28 Zdravilo za zmanjševanje telesne mase
For adults with severe hepatic impairment (Child-Pugh score: 10-15): fosamprenavir should be used with caution and at a reduced dose of 300 mg fosamprenavir twice daily with 100 mg ritonavir once daily.
Pri odraslih s hudo jetrno okvaro (ocena po Child-Pugh-u: 10-15): fosamprenavir je potrebno uporabljati previdno in v manjšem odmerku 300mg fosamprenavirja dvakrat na dan s 100 mg ritonavirja enkrat na dan.
For adults, adolescents, children and infants aged 1 year and older a booster dose can be given within the second year (i.e.
Pri odraslih, mladostnikih, otrocih in dojenčkih, starih vsaj 1 leto, je mogoče dati obnovitveni odmerek v drugem letu (tj.
For adults, dose reduction is recommended if the neutrophil count is < 750/mm3.
Pri odraslih je zmanjšanje odmerka priporočljivo, če je število nevtrofilcev < 750/mm3.
For adults, the initial dose is 5 g.
Začetni odmerek za odrasle je 5 g.
For adults, the recommended dose is 10 mg.
Priporočeni odmerek za odrasle je 10 mg
For advanced (accelerated or blast) phase CML and for Ph+ ALL, it is 140 mg.
V napredovalem obdobju KML (obdobju pospešene rasti ali obdobju blastne preobrazbe) in pri bolnikih s Ph+ ALL znaša odmerek 140 mg.
for adverse events including
neželenih učinkov.
for adverse events including
tveganja sistemskih učinkov
For adverse reactions observed with more than one component of a fixed-dose combination, the highest frequency is listed in the table below.
Za neželene učinke, ki so jih opažali pri več kot eni zdravilni učinkovini že pripravljene kombinacije zdravila je v spodnji preglednici navedena najvišja pogostnost.
For AIDS-related Kaposi’s sarcoma, the effectiveness of Caelyx was studied in two main studies involving 384 patients, including 77 who had received treatment before.
Učinkovitost zdravila Caelyx pri z aidsom povezanem Kaposijevem sarkomu so proučevali v dveh glavnih študijah, ki sta vključevali 384 bolnikov, vključno s 77 bolniki, ki so se zdravili že prej.
For Al/Al blisters and HDPE tablet container
Al/Al pretisni omot in HDPE vsebnik za tablete
For Al/Al blisters and HDPE tablet container:
Al/Al pretisni omot in HDPE vsebnik za tablete:
For Al/Al blisters and HDPE tablet container: 2 years.
Al/Al pretisni omot in HDPE vsebnik za tablete: 2 leti.
For Al/PVC/PVDC blister: 1 year.
Al/PVC/PVDC pretisni omot: 1 leto.
For Al/PVC/PVDC blister: Do not store above 30ºC.
Al/PVC/PVDC pretisni omot: Shranjujte pri temperaturi do 30°C.
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, once your anemia is corrected you will continue to receive Aranesp given as a single injection, either once a week or once every two weeks.
Vsi odrasli in pediatrični bolniki, stari  1 leta, s kronično odpovedjo ledvic bodo po korekciji anemije še naprej prejemali zdravilo Aranesp kot eno injekcijo enkrat na teden ali enkrat na dva tedna.
For all adult and paediatric patients ≥ 1 years of age with chronic renal failure, once your anemia is corrected you will continue to receive Aranesp given as a single injection, either once a week or once every two weeks.
Vsi odrasli in pediatrični bolniki, stari  1 leta, s kronično odpovedjo ledvic bodo po korekciji anemije še naprej prejemali zdravilo Aranesp kot eno injekcijo enkrat na teden ali enkrat na dva tedna.
For all adult and paediatric patients  1 year of age with chronic renal failure, Aranesp is given as a single injection by a healthcare professional, either under your skin (subcutaneous) or into a vein (intravenous).
Vsem odraslim in pediatričnim bolnikom, starim  1 leto, s kronično odpovedjo ledvic bo zdravilo Aranesp vbrizgal zdravstveni delavec v eni injekciji, in sicer pod kožo (subkutano) ali v veno (intravensko).
For all adult and paediatric patients  1 year of age with chronic renal failure, Aranesp is given as a single injection, either under your skin (subcutaneous) or into a vein (intravenous).
Vsem odraslim in pediatričnim bolnikom, starim  1 leto, s kronično odpovedjo ledvic vbrizgamo zdravilo Aranesp v eni injekciji, in sicer pod kožo (subkutano) ali v veno (intravensko).
For all adult and paediatric patients  1 year of age with chronic renal failure, Aranesp pre-filled pen is given as a single injection, under your skin (subcutaneous).
Vsem odraslim in pediatričnim bolnikom, starim  1 leto, s kronično odpovedjo ledvic vbrizgamo zdravilo Aranesp v napolnjenem injekcijskem peresniku kot eno injekcijo, in sicer pod kožo (subkutano).
For all adults and paediatric patients ≥ 11 years of age not on dialysis, Aranesp could also be given as an injection once monthly.
Vsem odraslim in pediatričnim bolnikom, starim  11 let, ki niso na dializi, je zdravilo Aranesp možno dati tudi kot injekcijo enkrat na mesec.
For all analysed subgroups (age, sensitivity to prior hormonal therapy, number of organs involved, status of bone-only lesions at baseline and presence of visceral metastasis, and across major demographic and prognostic subgroups) a positive treatment effect was seen with everolimus + exemestane with an estimated hazard ratio versus placebo + exemestane ranging from 0.25 to 0.60.
V vseh analiziranih podskupinah (glede na leta, občutljivost na predhodno hormonsko zdravljenje, število zajetih organov, izhodiščni status kostnih lezij in prisotnost visceralnih metastaz, pa tudi po podskupinah glede na glavne demografske značilnosti in prognostične dejavnike) so opažali pozitiven učinek zdravljenja s kombinacijo everolimusa in eksemestana, pri čemer je ocenjeno razmerje tveganj v primerjavi s skupino s placebom in eksemestanom znašalo od 0,25 do 0,60.
For all anti-epileptic drugs, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3 % in the general population.
Za vse antiepileptike so dokazali, da je pri potomcih zdravljenih žensk z epilepsijo prevalenca malformacij od dva- do trikrat višja kot stopnja v splošni populaciji, ki je približno 3 %.
For all of the endpoints described above, statistically significant results were also demonstrated in the OSI population.
Za vse zgoraj opisane opazovane dogodke so bili v 16. tednu rezultati statistično značilni tudi v populaciji OSI.
For all other patients, prescriptions of Thalidomide Celgene should be limited to 12 weeks and continuation of treatment requires a new prescription.
Za vse ostale bolnike je treba predpisovanje zdravila Thalidomide Celgene omejiti na 12 tednov zdravljenja.
For all patients under the age of 1 year of age, 3 mg/kg should be used to determine dose regardless of the weight of the patient.
Za vse bolnike, mlajše od 1 leta, je pri določitvi odmerka treba upoštevati odmerek 3 mg/kg ne glede na maso bolnika.
For all patients with cirrhosis irrespective of undetectable HCV RNA (target not detected) at weeks 4 or 12, an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks is recommended (see section 5.1).
Pri vseh bolnikih s cirozo, ne glede na nezaznavno koncentracijo HCV RNK (nezaznaven analit) v 4. ali v 12. tednu, je priporočljivo, da prejemajo samo peginterferon alfa in ribavirin še dodatnih 36 tednov, do skupnega trajanja zdravljenja 48 tednov (glejte poglavje 5.1).
For all patients with renal impairment, caution and close safety monitoring is advised. (See section 5.2)
Pri vseh bolnikih z okvaro ledvic se priporoča pozornost in skrbno nadziranje varnosti (glejte poglavje 5.2).
For all subjects who received parathyroid hormone 100 micrograms blood uric acid increase was reported for 8 subjects (0.6%) and hyperuricemia was reported for 5 subjects (0.4%).
Od vseh bolnic, ki so prejemale 100 g obščitničnega hormona, so zvišanje ravni sečne kisline v krvi odkrili pri 8 bolnicah (0,6%), hiperurikemijo pa pri 5 bolnicah (0,4%).
For all surgical procedures, Coagadex was assessed as excellent (no post-operative bleeding, no requirement of blood transfusions, and blood loss was no more than ‘as expected’) in controlling blood loss during and after surgery.
Pri vseh kirurških postopkih je bilo zdravilo Coagadex ocenjeno kot odlično (nobenih pooperativnih krvavitev, nobene potrebe po transfuzijah krvi, izguba krvi pa ni bila večja od “pričakovane”) pri nadzoru izgube krvi med in po operaciji.
For all these tests please refer also to the Patient Alert Card (inside your pack of STAYVEER tablets).
Za te preiskave si oglejte tudi Opozorilno kartico za bolnika (v škatli s tabletami zdravila STAYVEER).
For all these tests please refer also to the Patient Alert Card (inside your pack of STAYVEER tablets).
Za te preiskavesi oglejte tudi Opozorilno kartico za bolnika (v škatli s tabletami zdravila STAYVEER).
For all these tests please refer also to the Patient Alert Card (inside your pack of Tracleer tablets).
Za te preiskave si oglejte tudi Opozorilno kartico za bolnika (v škatli s tabletami zdravila Tracleer).
For all these tests please refer also to the Patient Alert Card (inside your pack of Tracleer tablets).
Za te preiskavesi oglejte tudi Opozorilno kartico za bolnika (v škatli s tabletami zdravila Tracleer).
For all three pharmaceutical forms:
Za vse tri farmacevtske oblike:
for allergy symptoms.
pri simptomih alergije.
For ALT (SGPT ) elevations between 2- and 3-fold the upper limit of normal, dose reduction to 10 mg may be considered and monitoring must be performed weekly.
V primeru zvišanja ALT (SGPT) med 2- in 3-kratno zgornjo mejo normalne vrednosti je treba razmisliti o zmanjšanju odmerka na 10 mg in vsak teden opravljati kontrole.
For ALT (SGPT) elevations between 2- and 3-fold the upper limit of normal, monitoring must be performed weekly.
V primeru zvišanja ALT (SGPT) med 2 - in 3-kratno zgornjo mejo normalnih vrednosti, je treba spremljanje izvajati vsak teden.
For Alu/Alu blisters
Za pretisne omote iz aluminija/aluminija
For Aluminium-aluminium blisters
Za Al-Al pretisne omote
For Aluminium-aluminium blisters
Za aluminijeve-aluminijeve pretisne omote
For an additional 115 subjects the RET mutational status could not be determined or was unclear.
Za dodatnih 115 oseb statusa mutacije RET ni bilo mogoče določiti ali ni bil jasen.
For an administered activity of 360 MBq the typical radiation dose to the target organ (brain) is 4.5 mGy.
Pri uporabljeni aktivnosti 360 MBq tipični odmerek sevanja, ki ga prejme ciljni organ (možgani), znaša 4,5 mGy.
For an administered activity of 360 MBq the typical radiation doses delivered to the critical organs, gallbladder, urinary bladder, upper large intestine wall, lower large intestine wall, small intestine and liver are 49.3 mGy, 25.0 mGy, 13.8 mGy, 12.6 mGy, 11.3 mGy and 13.9 mGy, respectively.
Pri prejeti aktivnosti 360 MBq tipični odmerki sevanja, ki jih prejmejo ključni organi, žolčnik, sečni mehur, stena zgornjega debelega črevesa, stena spodnjega debelega črevesa, tanko črevo in jetra, znašajo 49,3 mGy, 25,0 mGy, 13,8 mGy, 12,6 mGy, 11,3 mGy oziroma 13,9 mGy.
For an elderly subject (aged 84 years) with low bodyweight (35 kg) vilanterol AUC (0-24) is predicted to be 35% higher than the population estimate (subject with COPD aged 60 years and bodyweight of 70 kg), whilst Cmax was unchanged.
Za starejšega bolnika (starost 84 let) z majhno telesno maso (35 kg) je predvideni AUC(0-24) vilanterola 35 % višji od populacijske ocene (bolnik s KOPB, star 60 let in s telesno maso 70 kg), Cmax pa se ni spremenila.
for an enlarged prostate
pri povečani prostati
For an overdose of nicotinic acid, supportive measures should be employed.
V primeru prevelikega odmerjanja nikotinske kisline je treba uporabiti podporne ukrepe.
for an uneven heartbeat
proti neenakomernemu bitju srca
For angina, the starting dose should never exceed 5 mg twice daily in patients under 75 years of age.
Pri bolnikih z angino pektoris, ki so mlajši od 75 let, začetni odmerek nikoli ne sme preseči 5 mg dvakrat na dan.
For animal treatment
Samo za živali
For animal treatment only
Samo za živali - RpVet.
For animal treatment only (Reference is made to the pictogram of a dog in section 1).
(sklic na piktogram psa v poglavju 1)
For animal treatment only - to be supplied only on veterinary prescription
Samo za živali uporablja se le na osnovi recepta veterinarja.
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali - - Rp-Vet..
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali - na podlagi veterinarski recept.
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali uporablja se le na osnovi recepta veterinarja.
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali – na veterinarski recept
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali – na veterinarski recept.